| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Immunology | ||
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Immunology | ||
IND Submission example | IND | — | Subscribe to access the data. | Cell Therapies | Immunology |
Recent Updates
Recently added Catalysts
Cabaletta Bio, Inc.$2.72
+0.03 (+1.12%)
D 29Pipeline Score Overvalued Biotech · Clinical
Market Cap
595.15 M
EPS
-1.97
P/E Ratio
-
Value Trade
16.70 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
37.35 M
Operating CF
-42.56 M
Total Assets
148.15 M
Total Liabilities
44.84 M
Equity
103.31 M
D/E Ratio
12,345
4.29 %
Week
14.78 %
1 Month
18.89 %
3 Month
68.2 %
6 Month
-67.5 %
5 Year
-59.44 %
All Time
Cash Data
Cash Position
116.64 M
Monthly Burn
14.19 M
Runway
5.7 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
2.19 M
52 Week Range
1.26 - 4.23
% held by Insiders
12.43 %
% held by Institutions
53.25 %
Enterprise Value
504.97 M
Total Shares
111.31 M
Short %
38.94 %
Float Shares
105.30 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cabaletta Bio, Inc.
507Total events
12Upcoming
74Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
◆Topline Readoutrese-celFiledClinical Data
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-10-29 | rese-cel (resecabtagene autoleucel, formerly known as CABA-201) | phase 1/2 data readout | Phase 1/2 | — | – | – | – |
2025-10-29 | rese-cel (resecabtagene autoleucel, formerly known as CABA-201) | phase 1/2 data readout | Phase 1/2 | — | – | – | – |
2025-10-29 | rese-cel (resecabtagene autoleucel, formerly known as CABA-201) | phase 1/2 data readout | Phase 1/2 | — | – | – | – |
Drug Pipeline Intelligence
D29
Pipeline Score $38M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 35%
Micro Cap (rank 594 of 913)
Percentile RankCabaletta Bio, Inc. faces pipeline headwinds (29/100), with $189M risk-adjusted pipeline value, led by MuSK-CAART in MuSK Myasthenia Gravis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MuSK-CAART Monoclonal antibody | MuSK Myasthenia Gravis | Phase 1 | NCT05451212 | 22% | $123M | COMPLETED | 7 | - | - | Jul 24, 2025 | - | Nov 10, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rese-cel Fast TrackOrphan | dermatomyositis | Phase 1/2 | 2026-06-03 | 83% of dermatomyositis patients achieved the primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years. Read More | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress Read More | |
rese-cel Fast TrackOrphan | dermatomyositis | Phase 1/2 | 2026-06-03 | 83% of dermatomyositis patients achieved the primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years. Read More | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress Read More | |
rese-cel Fast TrackOrphan | dermatomyositis | Phase 1/2 | 2026-06-03 | 83% of dermatomyositis patients achieved the primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years. Read More | Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CABA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CABA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CABACabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Cabaletta Bio announced promising new data on rese-cel, showing that 83% of dermatomyositis patients achieved the primary endpoint in the Phase 1/2 RESET-Myositis study. The company also reported early positive findings in lupus and plans to initiate a registrational study for systemic sclerosis. The data were presented at the EULAR 2026 Congress, highlighting the potential of rese-cel in treating multiple autoimmune diseases.
Read more →CABACabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting A single infusion of the lowest dose of rese-cel administered without pre
Cabaletta Bio has presented new clinical and translational data for its investigational therapy, rese-cel, at the ASGCT 2026 Annual Meeting. The data highlights a 50% compelling drug-free response rate among refractory patients after receiving the lowest dose of rese-cel without preconditioning. The automated manufacturing process via the Cellares Cell Shuttle has shown promise in supporting scalability and reliability in production. This advancement could significantly enhance access to treatment for patients suffering from autoimmune diseases.
Read more →CABACabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV stud
Cabaletta Bio has announced its first quarter 2026 financial results alongside a significant update on its investigational therapy, rese-cel. The company reported promising initial data from the RESET-PV study, presenting potential drug-free clinical responses without preconditioning. The pivotal RESET-Myositis trial is advancing towards a Biologics License Application submission planned for next year. Additionally, Cabaletta closed a $150 million financing deal, suggesting robust momentum as it enters critical phases of development and commercialization.
Read more →CABA▲ +30.3%on this news· ran to +41% by day 1
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Cabaletta Bio has announced the pricing of an underwritten offering of 51,725,000 shares of common stock, expected to generate approximately $150 million. The offering is set to close on or about May 5, 2026, pending customary closing conditions. The financing has drawn interest from several prominent investors, including Bain Capital Life Sciences and Eli Lilly.
Read more →CABACabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Cabaletta Bio and Cellares have announced a 10-year commercial supply agreement for rese-cel, which aims to provide scalable and cost-effective production of this investigational CAR T cell therapy for autoimmune diseases. The partnership leverages Cellares' automated manufacturing platforms, enabling the production of thousands of batches annually. Initial patient data will be shared at the ASGCT conference in May 2026, supporting the planned BLA submission for myositis.
Read more →CABACabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Cabaletta Bio, Inc. announced multiple presentations at the ASGCT 2026 Annual Meeting, highlighting data on rese-cel, an investigational CAR T cell therapy. The presentations will cover clinical data from a low-dose cohort without preconditioning and initial results from automated manufacturing processes. The event will take place from May 11-15, 2026, in Boston, MA.
Read more →CABACellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Cellares has signed a 10-year commercial supply agreement with Cabaletta Bio for the automated manufacture of rese-cel, a CAR T cell therapy for autoimmune diseases. This collaboration aims to meet the growing global demand for rese-cel, following successful initial patient dosing. The automated manufacturing process is designed to enhance scalability and cost-efficiency, supporting broader patient access.
Read more →CABADisclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer
Cabaletta Bio, Inc. has published a presentation outlining their business operations, focusing on the development of rese-cel for autoimmune diseases. The document highlights ongoing clinical trials and the company's plans for future growth and partnerships. However, it also acknowledges various risks and uncertainties that could affect the success of their product candidates and overall strategy. The company emphasizes the importance of regulatory approvals and patient enrollment in the success of its development programs.
Read more →CABAFirst Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform
Cabaletta Bio has successfully infused the first two patients with its investigational CAR T cell therapy, rese-cel, manufactured using Cellares' automated Cell Shuttle platform. This milestone marks a significant advancement in the scalability and cost-effectiveness of autologous cell therapy production. The collaboration aims to enhance patient access to these transformative therapies for autoimmune diseases.
Read more →CABAFirst Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Cabaletta Bio has successfully dosed the first patients with its Rese-cel product, which is manufactured using Cellares' Automated Cell Shuttle™ platform. This milestone marks a significant advancement in the clinical development of Rese-cel, showcasing the potential of automated cell manufacturing technology. The collaboration aims to improve the efficiency and scalability of cell therapy production.
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio reported its financial results for Q4 and full year 2025, highlighting progress in its rese-cel program for autoimmune diseases. The company is on track for a BLA submission in 2027 and is advancing innovative manufacturing processes. Upcoming clinical data is anticipated to support regulatory discussions, while the company continues to manage increased R&D expenses.
Read more →CABA▲ +13.4%on this news
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio, Inc. will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company focuses on developing targeted cell therapies for autoimmune diseases. A live webcast of the presentation will be available, with replays for 30 days. This event highlights the company's ongoing commitment to innovation in the biotech field.
Read more →CABA▼ -7.2%on this news
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cabaletta Bio, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company is focused on developing curative targeted cell therapies for autoimmune diseases, with its lead investigational therapy, rese-cel, currently evaluated in the RESET clinical program. A live webcast of the presentation will be available on their website.
Read more →CABA▲ +5.2%on this news
Cabaletta Bio Announces 2026 Strategic Priorities Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a si
Cabaletta Bio has outlined its strategic priorities for 2026, focusing on advancing the development and commercialization of its investigational CAR T cell therapy, rese-cel, for autoimmune diseases. The company is actively enrolling in a pivotal myositis trial, aiming for a BLA submission in 2027, with a 17-patient cohort designed to evaluate treatment efficacy. Additionally, the FDA has granted clearance for the automated manufacturing of rese-cel, which could improve scalability and reduce costs. Important clinical data is anticipated in 2026, which could inform the future direction of their product's development and regulatory strategies.
Read more →CABA▲ +5.2%on this news
Cabaletta Bio Announces 2026 Strategic Priorities
Cabaletta Bio has outlined its strategic priorities for 2026, focusing on the development and launch of rese-cel, an investigational CAR T cell therapy. The company is actively enrolling patients in pivotal trials for myositis and aims for a Biologics License Application submission in 2027. Innovations in fully automated manufacturing processes are expected to enhance scalability and effectiveness. Additionally, promising durability data is anticipated from ongoing clinical trials, with the potential to improve access to therapy for autoimmune disease patients.
Read more →CABACabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio reported its third quarter 2025 financial results, highlighting promising data for its investigational therapy, rese-cel, in treating autoimmune diseases. The company plans to submit a Biologics License Application (BLA) for rese-cel in 2027, following successful outcomes in a registrational cohort. Additionally, FDA alignment on further trial designs is anticipated by the end of 2025.
Read more →CABA▼ -10.3%on this news
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Cabaletta Bio, a clinical-stage biotechnology company, has announced its participation in upcoming investor conferences in November and December. The company is dedicated to developing curative targeted cell therapies for autoimmune diseases, with its lead investigational therapy, rese-cel, currently evaluated in the RESET clinical program. Webcasted fireside chats will be accessible on their website.
Read more →CABA▼ -8.8%on this news
Corporate Presentation October 2025 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the prese
Cabaletta Bio has prepared a corporate presentation outlining its strategic plans and forward-looking statements regarding its autoimmune-focused pipeline, particularly the development of its drug candidate, rese-cel. The presentation highlights ongoing clinical trials, including RESET-Myositis, RESET-SLE, and other trials aimed at demonstrating the drug's safety and efficacy. However, the company acknowledges various risks and uncertainties that may impact the success and timelines of these trials, including enrollment rates and potential regulatory challenges.
Read more →CABA▲ +13%on this newsshared move
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio presented encouraging clinical data for its investigational therapy rese-cel at ACR Convergence 2025. Key findings include significant improvements in myositis and systemic sclerosis patients, with plans to initiate a registrational trial for myositis. The RESET-SLE trial is also expanding to include a cohort without preconditioning, aiming for simpler treatment options for lupus patients.
Read more →CABACabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registration
Cabaletta Bio reported encouraging clinical data for its investigational therapy rese-cel at the ACR Convergence 2025. In trials for myositis, systemic sclerosis, and lupus, significant positive outcomes were noted, including major TIS responses and the initiation of a new myositis trial. The company also plans to expand the RESET-SLE trial with a no preconditioning cohort following promising initial responses. However, some patients faced grade 1 or 2 cytokine release syndrome, indicating the need for continued safety monitoring as trials progress.
Read more →CABA▲ +16.1%on this news
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio has appointed Steve Gavel as Chief Commercial Officer to lead global commercial strategy for rese-cel, an investigational therapy targeting autoimmune diseases. Gavel brings extensive experience from Legend Biotech, where he successfully launched CARVYKTI. The company plans to submit a Biologics License Application for rese-cel in 2027, enhancing its commercial planning and execution capabilities.
Read more →CABA▲ +18%on this newsshared move
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
Cabaletta Bio presented promising initial data from the RESET-PV trial at the 2025 ESGCT Annual Congress, showing complete B cell depletion and early clinical responses in patients with pemphigus vulgaris treated with rese-cel without preconditioning. The trial indicates potential for expanding treatment options for autoimmune diseases. All adult cohorts in related trials are fully enrolled.
Read more →CABACabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress – Complete B cell depletion, rapid reduction in aut
Cabaletta Bio presented promising data on its Rese-cel therapy without preconditioning at the 2025 ESGCT Annual Congress. The therapy achieved complete B cell depletion and early clinical responses in two of three patients with pemphigus vulgaris, who remained off immunomodulators. Notably, CAR T cell expansion was comparable to previous studies with preconditioning. The company plans to expand patient enrollment and explore higher doses based on these encouraging findings.
Read more →CABACorporate Presentation September 2025 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the pre
Cabaletta Bio, Inc. presented a corporate update highlighting its advancements in developing targeted cellular therapies for autoimmune diseases, particularly focusing on their product, rese-cel. The company reported that over 70 clinical sites are currently recruiting patients across six indications. A Biologics License Application (BLA) submission for myositis is anticipated in 2027, marking a significant step in their development pipeline. This presentation includes forward-looking statements regarding the expectations and strategies for growth in their autoimmune-focused therapies.
Read more →CABACabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in several upcoming investor conferences throughout September 2025. The company will hold webcasted fireside chats and meetings with investors at major events, including the Cantor Global Healthcare Conference and the Wells Fargo Healthcare Conference. This engagement reflects Cabaletta's commitment to advancing its clinical-stage therapies aimed at autoimmune diseases, particularly through its CARTA strategy. The company's flagship therapy, rese-cel, is under evaluation in the RESET clinical development program across various therapeutic areas.
Read more →CABACabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Cabaletta Bio reported its Q2 2025 financial results and provided updates on its Rese-cel program. The company is on track to begin registrational cohort enrollment for Rese-cel in myositis in the second half of 2025, anticipating a BLA submission in 2027. Recent data from clinical trials demonstrated significant efficacy, with nearly all enrolled patients off immunomodulatory medications. Additionally, Cabaletta has secured funding through a public offering to support its late-stage development activities, extending its cash runway.
Read more →CABACabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update – Registrational cohort enrollment in RESET-Myositis trial on track to start in 2H25 with anticipated 2027 BLA submission fo
Cabaletta Bio announced its Q2 2025 financial results and provided a business update regarding its investigational therapy, rese-cel, aimed at treating autoimmune diseases. The company reported that enrollment for the RESET-Myositis trial is on schedule, with a Biologics License Application submission anticipated for 2027. Significant progress was noted in clinical data, revealing positive therapeutic responses and patient outcomes across various cohorts. Cabaletta's recent public offering has bolstered its financial resources, enabling continued development and commercialization efforts.
Read more →CABACabaletta Bio Announces Pricing of Public Offering of Securities
Cabaletta Bio has announced the pricing of a public offering, aiming to raise about $100 million through the sale of 39.2 million shares of common stock and accompanying warrants. The offering is expected to close on June 12, 2025, subject to customary conditions. The proceeds will support the development of targeted cell therapies for autoimmune diseases.
Read more →CABA▼ -25.5%on this newsshared move
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
Cabaletta Bio announced promising new data for rese-cel, a targeted cell therapy, at the EULAR 2025 Congress. The data showed significant clinical responses in patients with myositis, lupus, and scleroderma, with many achieving remission while off immunomodulators. The company is on track for registrational discussions with the FDA for multiple autoimmune indications.
Read more →CABA▼ -25.5%on this newsshared move
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio, Inc. has announced a proposed public offering of shares and accompanying warrants to strengthen its financial position and support the development of its targeted cell therapies for autoimmune diseases. The offering, led by Jefferies, TD Cowen, and Cantor, entails a 30-day option for underwriters to purchase additional shares. Closing of the offering is anticipated around June 12, 2025, contingent on customary conditions. However, market conditions and other uncertainties could impact the offering's completion and terms.
Read more →CABACabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress 7 of 8 myositis patients achieved clinically meaningful TIS respon
Cabaletta Bio announced positive clinical data for rese-cel at the EULAR 2025 Congress, highlighting significant efficacy in patients with myositis, lupus, and scleroderma. The data revealed that a majority of myositis patients achieved meaningful responses after discontinuing immunomodulators, while all SLE patients without nephropathy attained remission. Cabaletta is advancing discussions with the FDA for registrational pathways for SLE, scleroderma, and myasthenia gravis. The company continues to accelerate enrollment in its RESET trial program, which demonstrates a promising approach to autoimmunity treatment.
Read more →CABACabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio, a clinical-stage biotechnology company, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 4, 2025, in New York City. The company aims to develop curative targeted cell therapies for autoimmune diseases and is currently evaluating its lead investigational therapy, rese-cel, in its RESET clinical development program. A live webcast of the presentation will be available on their website, with replays accessible for 30 days afterward.
Read more →CABA▲ +39.2%on this news· ran to +56% by day 1
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
Cabaletta Bio, Inc. announced plans for a BLA submission for its investigational therapy rese-cel by 2027, following a successful FDA meeting regarding cohort design for the RESET-Myositis trial. The company aims to assess the therapy's effectiveness in treating myositis, a severe autoimmune condition affecting around 80,000 patients in the U.S. The FDA has granted RMAT designation for rese-cel, allowing for expedited review and more frequent interactions during development. Cabaletta is also focusing on optimizing its manufacturing processes to support commercial readiness.
Read more →CABACabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts – Two subtype specific cohorts with ~15 patients each added to the ongoing RESE
Cabaletta Bio has announced plans to submit a Biologics License Application (BLA) for its investigational therapy rese-cel for myositis by 2027, following recent discussions with the FDA. The FDA has granted RMAT designation for rese-cel, which will support expedited development and potential approval pathways. The company is expanding the RESET-Myositis trial to include two subtype-specific cohorts, each with approximately 15 patients, as they proceed with clinical evaluation for Hashimoto’s disease and other related conditions. Promising new clinical data on rese-cel in various autoimmune diseases will be presented at upcoming congresses.
Read more →CABA▼ -10.6%on this news· ran to -25% by day 1
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Cabaletta Bio, Inc. reported its financial results for Q4 and the full year 2024, highlighting significant progress in its clinical development programs for rese-cel, an investigational therapy for autoimmune diseases. The company is on track to meet with the FDA regarding registrational trials for myositis, and clinical data shows promising results from patients in several trial cohorts. However, a recent protocol deviation in the RESET-SSc trial led to a patient experiencing dose-limiting toxicity. Despite these challenges, Cabaletta maintains a strong financial position to support operations into the first half of 2026.
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – –
Cabaletta Bio has reported its financial results for the fourth quarter and full year 2024, highlighting a strong cash position of $164 million that supports ongoing development into 2026. The company is gearing up for a meeting with the FDA to align on registrational trial designs for its investigational therapy, rese-cel, aimed at treating myositis. While early clinical results show promise, the company also faced protocol deviations and adverse patient reactions in clinical trials, underlining the complexities of their developmental process. Overall, the company's operational status and future plans indicate a positive outlook despite some challenges.
Read more →CABACabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
Cabaletta Bio, Inc. is participating in the TD Cowen 45th Annual Health Care Conference scheduled for March 3, 2025, in Boston, MA. The clinical-stage biotechnology company focuses on developing targeted cell therapies for autoimmune diseases. The company's lead investigational therapy, rese-cel, is currently undergoing evaluation in its RESET clinical development program across several therapeutic areas. A live webcast of the presentation will be accessible on the company's website, with replays available for 30 days.
Read more →CABA▼ -14%on this news
Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question an
Cabaletta Bio, Inc. has released a corporate presentation that outlines the company's informational status regarding its products and operations as of February 2025. The presentation includes forward-looking statements concerning the business, research developments, and clinical trials, such as its pipeline for autoimmune disease therapies. It also highlights potential benefits and important insights related to its CAAR T technology. The company provides disclaimers regarding the completeness and accuracy of the information presented, cautioning against undue reliance on any forward-looking statements.
Read more →CABA▼ -14%on this news
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Cabaletta Bio announced updated clinical data for rese-cel, highlighting positive outcomes in patients with autoimmune diseases. In trials, several patients achieved significant clinical responses, including remission from systemic lupus erythematosus (SLE) and complete renal response in lupus nephritis (LN). A favorable safety profile was noted, with a majority of patients experiencing low toxicity levels. The company continues to enroll patients across multiple clinical sites in the U.S. and Europe, aiming to accelerate trial progress and further explore rese-cel's potential in treating autoimmune diseases.
Read more →CABA▲ +8.9%on this newsshared move
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings Clinical efficacy continued to deepen over time with thre
Cabaletta Bio has released updated clinical data showing significant efficacy of its investigational therapy, rese-cel, in treating autoimmune diseases across several trials. Notably, three patients with systemic lupus erythematosus reached DORIS remission, marking a promising outcome for the therapy. In addition, one patient with lupus nephritis achieved complete renal response, and another with dermatomyositis showed major treatment improvement while discontinuing immunosuppressants. The therapy's safety profile remains favorable, as reported by the first 10 dosed patients within the RESET program.
Read more →CABACabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
Cabaletta Bio, a clinical-stage biotechnology company, announced plans to present updated clinical data on its investigational therapy, rese-cel, at two prominent scientific meetings in February 2025. The presentations will cover safety, translational data, and clinical outcomes from the first patients dosed in the RESET clinical program targeting autoimmune diseases. Additionally, the company emphasizes the potential of rese-cel to reset the immune system and provide durable responses to treatment without chronic therapy requirements.
Read more →CABACabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference in New York on February 5, 2025. The company specializes in developing targeted cell therapies for autoimmune diseases and is advancing its lead investigational therapy, rese-cel, in the RESET clinical program. A live webcast of the event will be available on their website, showcasing their commitment to transparency and investor relations.
Read more →CABACabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
Cabaletta Bio, Inc. has outlined its strategic priorities and key milestones for 2025, focusing on the development of its investigational therapy, rese-cel. The company plans to align with the FDA on registrational trial designs and has observed a positive safety profile in early patient trials. With 44 active sites and ongoing patient enrollment, Cabaletta aims to present new clinical data at upcoming scientific meetings. The company is also expanding its clinical supply and operational capabilities to support its increased clinical trials.
Read more →CABACorporate Presentation JANUARY 2025 2025 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the informa
Cabaletta Bio presented an overview of their current business strategies and clinical developments in January 2025. The focus remains on their CAAR T technology and the advancement of the autoimmune-focused pipeline, including their product candidate rese-cel. However, the company faces several risks related to clinical trial success, patient enrollment, and demonstrating efficacy. The presentation highlights the company's forward-looking statements, emphasizing both potential benefits and inherent uncertainties.
Read more →CABA▲ +5.7%on this news· ran to +80% by day 3
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in several investor conferences in December 2024, including the Evercore HealthCONx Conference and Citi's Global Healthcare Conference. Management will be available for one-on-one meetings, and the Company will host a fireside chat. This engagement aims to highlight the company's advancements in curative targeted cell therapies for autoimmune diseases, particularly through its CABA™ platform and the CABA-201 investigational therapy.
Read more →CABA▼ -10.9%on this news· ran to -38% by day 3
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Cabaletta Bio presented new clinical data on CABA-201 at the ACR Convergence 2024, highlighting promising safety and efficacy results. The therapy, designed for patients with refractory autoimmune diseases, showed no severe cytokine release syndrome in the majority of patients and compelling responses, including drug-free benefits. The ongoing clinical trials involve eight patients, with complete B cell depletion observed and signs of early positive clinical outcomes. The company anticipates potential discussions with the FDA regarding future trial designs in 2025.
Read more →CABA▼ -5.7%on this news· ran to -37% by day 3shared move
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update – Clinical data from the RESET-Myositis and RESET-SLE trials, along with initial clinical data from the RESET-SSc trial, to b
Cabaletta Bio reported its third quarter 2024 financial results, highlighting progress in its clinical trials for CABA-201. Notably, they are set to present data from the RESET trial program at ACR Convergence 2024, where patient enrollment is ongoing across the U.S. and Europe. The company has a strong cash position, expected to fund operations into the first half of 2026, and is planning to meet with the FDA regarding potential registration program designs for CABA-201. Additionally, they have expanded their leadership team to enhance international clinical development efforts.
Read more →CABACABA-201 Clinical and Translational Data from the RESET Phase 1/2 Trials NOVEMBER 2024 2024 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these sli
Cabaletta Bio has presented information regarding its clinical and translational data from the RESET Phase 1/2 trials for CABA-201, an investigational therapy aimed at treating autoimmune diseases. The company anticipates significant clinical data read-outs in late 2024 that may provide insights into the safety and efficacy of CABA-201 across multiple conditions. Despite the optimistic outlook, the presentation also outlines various risks associated with clinical trials, regulatory approvals, and patient enrollment challenges.
Read more →CABA▲ +10.7%on this news
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Cabaletta Bio, Inc. has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference scheduled for November 11, 2024, in Boston, MA. The company is focused on developing the first curative targeted cell therapies for autoimmune diseases, leveraging its CABA™ platform. Its lead product candidate, CABA-201, is part of clinical trials aimed at treating various autoimmune conditions. The event will feature a live webcast, which will be accessible for 30 days post-event.
Read more →CABACabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio announced it will present new clinical data on CABA-201 at the ACR Convergence 2024. The therapy is being evaluated in ongoing trials for autoimmune diseases, specifically targeting immune-mediated necrotizing myopathy and systemic lupus erythematosus. Presentation details include a safety and efficacy study of CABA-201 and correlative studies, both slated for mid-November 2024. This development highlights Cabaletta's commitment to advancing targeted cell therapies in the field of autoimmune treatment.
Read more →CABA▼ -34.4%on this news
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio reported its second-quarter financial results, highlighting strong enrollment across multiple RESET clinical trials for autoimmune diseases. Positive initial clinical data were presented at the EULAR 2024 Congress, showing promising results for the CABA-201 treatment. However, a patient in the lupus nephritis cohort experienced a serious dose-limiting toxicity, though the study will continue without delay at the same dose based on committee recommendations. The company also announced new manufacturing strategies and the addition of Dr. Sarah Yuan as Chief Technology Officer to advance its clinical product pipeline.
Read more →CABACabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update Nine patients enrolled as of
Cabaletta Bio, Inc. reported its financial results for the second quarter of 2024, highlighting progress in its clinical development program. As of August 5, nine patients are enrolled in the RESET trials, with additional participation since the EULAR Congress in June. Initial clinical data for CABA-201, which aims to provide targeted therapies for autoimmune diseases, was discussed at the event. Despite a patient experiencing a serious adverse event, the trial will continue based on the recommendations of the data monitoring committee. The company maintains a solid financial outlook, with substantial cash reserves to support ongoing operations through mid-2026.
Read more →CABA▼ -5.4%on this news
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
Cabaletta Bio, Inc. (Nasdaq: CABA) announced its participation in the Stifel 2024 Virtual Cell Therapy Forum, scheduled for July 9, 2024. CEO Steven Nichtberger will engage in a fireside chat at the event, which aims to spotlight advancements in cell therapy. The company is advancing its CABA platform, focusing on engineered T cell therapies to treat autoimmune diseases. Live and recorded presentations will be accessible via the company's website.
Read more →CABA▼ -15.1%on this news· ran to -34% by day 3
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
Cabaletta Bio reported promising initial clinical data from its Phase 1/2 RESET-Myositis and RESET-SLE trials for the investigational therapy CABA-201. The early results indicated no serious adverse events and complete B cell depletion in both patients within 15 days post-infusion. Improvements in specific disease measures were noted, suggesting CABA-201 may facilitate an immune system reset. The company plans to accelerate clinical trial enrollment and expects to release more data from ongoing trials later this year.
Read more →CABA▲ +13%on this news
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201
Cabaletta Bio reported its financial results for the first quarter of 2024, highlighting positive early safety data from the RESET-Myositis and RESET-SLE trials, with no CRS or ICANS observed in the initial patients dosed with CABA-201. The company is poised to present initial clinical data at the EULAR 2024 Congress in June. Additionally, Cabaletta is advancing innovations aimed at enhancing patient experience, including a study to evaluate CABA-201 without preconditioning. The company is confident in its strategy to deliver targeted therapies for autoimmune diseases.
Read more →CABACabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology company, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, scheduled for May 20, 2024. The company specializes in developing targeted cell therapies aimed at treating autoimmune diseases and is currently evaluating its lead product candidate, CABA-201, in clinical trials. A live webcast of the event will be available on their website, indicating a commitment to transparency and investor relations.
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program Initial clinical dat
Cabaletta Bio has reported its financial results for Q4 and the full year of 2023, revealing significant progress in its clinical development. The company has successfully dosed its first patient with CABA-201 in the RESET clinical trials, aiming to treat various autoimmune diseases. Additionally, CABA-201 has received Rare Pediatric Disease designation from the FDA, underscoring the urgency of treatments for underserved conditions. With a robust cash position extending into 2026, Cabaletta appears well-equipped to advance its therapeutic programs.
Read more →CABACabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis PHILADELPHIA
Cabaletta Bio has announced that the FDA granted Orphan Drug Designation to its investigational cellular therapy, CABA-201, for treating systemic sclerosis, a severe autoimmune disease. This designation is significant as it provides potential incentives like clinical trial tax credits and market exclusivity. CABA-201 is part of the RESET clinical trial program, which aims to evaluate the therapy's effectiveness across several autoimmune conditions. With limited treatment options currently available for systemic sclerosis, this development could significantly impact patient care.
Read more →CABACabaletta Bio to Participate in Upcoming Investor Conferences in March
Cabaletta Bio, a biotechnology company specializing in targeted cell therapies for autoimmune diseases, has announced its participation in upcoming investor conferences in March 2024. CEO Steven Nichtberger will lead a fireside chat at the TD Cowen 44th Annual Health Care Conference in Boston, and management will also be present for one-on-one meetings at the Jefferies Biotech on the Bay Summit in Miami. The company emphasizes its commitment to developing its CABA platform and clinical-stage products aimed at offering curative treatments.
Read more →CABACabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis PHILADELPHIA
Cabaletta Bio, Inc. announced that the FDA has granted Orphan Drug Designation to its investigational therapy CABA-201 for treating myositis, a rare autoimmune disease. CABA-201 is designed to deplete CD19-positive B cells, potentially enabling durable remissions. The therapy is currently being evaluated in the RESET-Myositis trial, aiming to address the unmet needs of patients who currently have inadequate treatment options. This designation not only highlights the potential benefits of CABA-201 but also qualifies Cabaletta for various incentives aimed at bringing new treatments to patients.
Read more →CABACabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. CEO Steven Nichtberger, M.D., will be involved in a fireside chat during the event in New York, NY. The company is known for its development of engineered T cell therapies targeting autoimmune diseases, with its lead candidates undergoing clinical evaluation. A live webcast of the event will be made available on the company’s website.
Read more →CABA▲ +8.7%on this news
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
Cabaletta Bio has announced that the FDA has granted Fast Track Designations for CABA-201, an investigational CAR T cell therapy, for the treatment of dermatomyositis and systemic sclerosis. This marks the second and third Fast Track Designations for CABA-201, which is also designated for systemic lupus erythematosus. These designations may help accelerate the therapy's development and review, addressing significant unmet medical needs in autoimmune disorders. CABA-201 aims to deeply deplete CD19-positive B cells, which may lead to a potential immune system reset for affected patients.
Read more →CABA▲ +8.7%on this news
Corporate Presentation JANUARY 2024 2024 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the informa
Cabaletta Bio has delivered a corporate presentation outlining its current status and future plans in relation to its product candidate CABA-201, which is being developed for autoimmune diseases. The company highlighted the expected benefits of CABA-201, including its potential to enable an 'immune system reset.' Initial clinical trial results are anticipated in 2024. However, the presentation also notes several risks, including the challenges of demonstrating safety and efficacy and potential enrollment issues in upcoming trials.
Read more →CABACabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology firm specializing in targeted cell therapies for autoimmune diseases, has announced its participation in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2024. Steven Nichtberger, M.D., the CEO, will deliver a presentation detailing the company's advancements and product candidates, including CABA-201 for systemic lupus erythematosus and other autoimmune conditions. A webcast of this presentation will be available live and for replay for 30 days on the company’s website.
Read more →CABA▼ -26.8%on this news
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, led by CEO Steven Nichtberger. The event will feature a fireside chat highlighting the company's innovative approaches to treating autoimmune diseases through engineered T cell therapies. Cabaletta's platforms, including CARTA and CAART, aim to develop potentially curative options for various autoimmune conditions. A live webcast of the presentation will be available on the company's website.
Read more →CABACabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 202
Cabaletta Bio has reported its financial results and business updates for Q3 2023. The company is advancing its CABA-201 program in clinical trials for lupus and myositis, with initial data expected in early 2024. Additionally, Cabaletta has expanded its clinical development to include conditions like systemic sclerosis and generalized myasthenia gravis. Their financial position appears stable, with adequate funding projected into the fourth quarter of 2025 as they pursue regulatory advancements and patient enrollment in their studies.
Read more →CABACabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth
Cabaletta Bio has achieved FDA clearance for its CABA-201 IND application for treating generalized myasthenia gravis (gMG), marking a significant step forward in clinical development. This approval is notable as it represents the first CD19-CAR T IND application cleared for gMG and the company's fourth IND clearance for CABA-201 in various autoimmune diseases. The upcoming Phase 1/2 clinical trial will evaluate CABA-201 across two cohorts of gMG patients, enhancing the potential therapeutic landscape for this rare disease. The company is positioning itself to deliver initial clinical data from ongoing studies in the first half of 2024.
Read more →CABA▲ +7.5%on this news· ran to +21% by day 3
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
Cabaletta Bio, Inc. announced its participation in three upcoming investor conferences in November, including events hosted by Guggenheim, Stifel, and Evercore ISI. The Chief Executive Officer, Steven Nichtberger, and other management members will engage in fireside chats and one-on-one meetings to discuss the company’s focus on targeted cell therapies for autoimmune diseases. These activities indicate the company's proactive approach to investor engagement and highlight its ongoing efforts in clinical development.
Read more →CABACabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
Cabaletta Bio has received FDA clearance for its third IND application concerning CABA-201, a therapy aimed at systemic sclerosis. This Phase 1/2 trial will assess its effects in two patient cohorts, targeting severe skin and organ manifestations. Initial results from CABA-201 for lupus and myositis trials are expected by mid-2024, showcasing optimism for broader applications of the therapy within autoimmune diseases.
Read more →CABACorporate Presentation OCTOBER 2023 2023 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the informa
Cabaletta Bio presented a corporate update outlining its strategies and advancements. The company is focused on developing its CAAR T and CARTA technologies, with upcoming Phase 1/2 clinical trials for CABA-201 aimed at patients with autoimmune diseases. Despite potential opportunities, Cabaletta acknowledges various risks, including regulatory uncertainties and the challenges of clinical trial enrollments. The presentation emphasizes that forward-looking statements may not guarantee success due to numerous uncertainties involved in drug development.
Read more →CABACabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
Cabaletta Bio, Inc. will participate in several investor conferences in September 2023, including the Wells Fargo Healthcare Conference and H.C. Wainwright Global Investment Conference. The events will feature key management presentations and discussions on the company's development of targeted cell therapies for autoimmune diseases. These appearances aim to increase investor engagement and showcase the firm’s innovative therapies including their CABA™ platform. The company’s headquarters are located in Philadelphia, PA.
Read more →CABACabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of pat
Cabaletta Bio has expanded its GMP manufacturing agreement with WuXi Advanced Therapies to include CABA-201, aiming for commercial readiness in various clinical trials. The partnership builds on past collaborations focused on producing innovative cell therapies. CABA-201 targets autoimmune diseases, with planned trials for conditions such as systemic lupus erythematosus and myositis. The agreement highlights Cabaletta's commitment to enhancing its therapeutic pipeline and addressing pressing patient needs.
Read more →CABACabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN Strengthened bal
Cabaletta Bio reported its second quarter financial results and business updates, highlighting significant advancements in its clinical programs. The company received clearance for a second IND application for CABA-201 in myositis and secured Fast Track Designation for its therapies in systemic lupus erythematosus and lupus nephritis. With a strengthened balance sheet thanks to a recent $100 million public offering, Cabaletta has extended its cash runway into the fourth quarter of 2025, supporting its ongoing efforts to develop targeted cell therapies for autoimmune diseases.
Read more →CABA▼ -6.7%on this news
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition b
Cabaletta Bio has appointed Shawn Tomasello, a seasoned leader with over 35 years in the life sciences, to its Board of Directors. Ms. Tomasello is known for her crucial role in the global commercialization of Yescarta at Kite Pharma and brings valuable experience in scaling commercial organizations. Her appointment is expected to provide important insights as Cabaletta continues to advance its CABA-201 development program, aimed at treating patients with autoimmune diseases. The company is focused on the development of innovative and potentially curative cell therapies.
Read more →CABACabaletta Bio to Present at the Jefferies Healthcare Conference
Cabaletta Bio, a clinical-stage biotechnology company, will present at the Jefferies Healthcare Conference on June 7, 2023. CEO Steven Nichtberger will share insights on the company’s innovative approach to developing targeted cell therapies for autoimmune diseases. The company’s CABA platform includes promising therapies aimed at conditions such as systemic lupus erythematosus and myasthenia gravis. A live webcast of the event will be available on their website, with replays accessible for 30 days afterward.
Read more →CABACabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares PHILADELPHIA
Cabaletta Bio has announced the completion of a public offering that raised $100 million by selling 8,337,500 shares of common stock at a price of $12.00 per share, which included the full exercise of an over-allotment option. The proceeds will support the company's efforts in developing innovative targeted cell therapies for autoimmune diseases. The offering was managed by several financial institutions, including TD Cowen, Evercore ISI, and Guggenheim Securities. This substantial capital can enhance Cabaletta Bio's project advancement as it continues to work on engineered T cell therapies.
Read more →CABA▼ -7.8%on this newsshared move
Cabaletta Bio Announces Pricing of Public Offering of Common Stock PHILADELPHIA
Cabaletta Bio, based in Philadelphia, has announced the pricing of a public offering for 7,250,000 shares of its common stock at $12.00 per share, expected to generate $87 million in gross proceeds. The offering, which is set to close on May 22, 2023, will primarily support the clinical development of CABA-201 and advance manufacturing capabilities for upcoming trials. Joint book-running managers include TD Cowen, Evercore ISI, and Guggenheim Securities. The offering is being made under an effective registration statement previously filed with the SEC.
Read more →CABA▼ -7.8%on this newsshared move
Cabaletta Bio Announces Proposed Public Offering of Common Stock
Cabaletta Bio, Inc. has announced a proposed public offering of its common stock, all of which is being offered by the company itself. The offering will include a 30-day option for underwriters to purchase an additional 15% of the shares. While the plan indicates potential growth for Cabaletta as it develops innovative therapies for autoimmune diseases, the completion of this offering will depend on market conditions and other uncertainties.
Read more →CABA▲ +14.6%on this newsshared move
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose
Cabaletta Bio, Inc. has received FDA clearance for its IND application for CABA-201, intended for a Phase 1/2 clinical trial targeting patients with various subtypes of myositis. The trial will involve separate cohorts for dermatomyositis, anti-synthetase syndrome, and immune-mediated necrotizing myopathy. This clearance comes just two months after Cabaletta's initial IND approval for a separate drug in systemic lupus erythematosus. The company aims to evaluate the therapeutic potential of CABA-201 to reset the immune system and provide durable responses for autoimmune disease patients.
Read more →CABA▲ +6.7%on this newsshared move
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted
Cabaletta Bio reported its financial results for the first quarter of 2023, highlighting the approval of its IND application for CABA-201 to treat patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE). The FDA granted Fast Track Designation for this novel treatment, allowing for expedited development. A Phase 1/2 clinical trial is planned to evaluate the safety and efficacy of CABA-201 in a cohort of patients. The company is positioned to advance its clinical programs due to its experienced team and strategic focus on autoimmune diseases.
Read more →CABACabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting PHILADELPHIA
Cabaletta Bio, Inc. announced that Dr. Samik Basu will present an oral presentation on CD 19 CAR T-cells for systemic lupus erythematosus at the ASGCT 26th Annual Meeting. The company will also showcase new preclinical data for its investigational therapy CABA-201 and updated information from the ongoing DesCAARTes trial concerning DSG3-CAART for mucosal pemphigus vulgaris. These presentations are scheduled for May 16-20, 2023, at the Los Angeles Convention Center.
Read more →CABA▲ +9.8%on this newsshared move
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
Cabaletta Bio has received FDA Fast Track Designation for its investigational therapy CABA-201, aimed at treating systemic lupus erythematosus (SLE) and lupus nephritis (LN). The therapy utilizes a CD19-CAR T cell approach to deplete CD19-positive B cells. Cabaletta plans to conduct a Phase 1/2 clinical trial involving 12 patients with active SLE, addressing the significant unmet need for curative treatment options in this patient population. The potential of CABA-201 reflects important advances in biopharmaceutical therapies for autoimmune diseases.
Read more →CABA▼ -5.9%on this news· ran to +21% by day 3
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Cabaletta Bio, Inc. announced that its CEO, Steven Nichtberger, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. The discussion will focus on the company's innovative targeted cell therapies for autoimmune diseases. The presentation will be available via live webcast, with replays accessible for 30 days on their website. This engagement aims to enhance investor understanding of Cabaletta’s development programs and strategies.
Read more →CABACabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
Cabaletta Bio, Inc. is set to present at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023. The company's CEO, Dr. Steven Nichtberger, will provide insights into their innovative approaches to autoimmune disease therapies. Cabaletta Bio is advancing its development of engineered T cell therapies, with a focus on offering potentially curative treatments. The live presentation will be accessible through their website, with replays available for a month following the event.
Read more →CABA▲ +16.5%on this news
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
Cabaletta Bio, Inc. has received FDA clearance for its IND application for CABA-201, a CAR T-cell therapy aimed at treating systemic lupus erythematosus (SLE). This IND clearance was achieved in just six months post-licensing the CABA-201 binder, underscoring the company's development efficiency. The upcoming Phase 1/2 clinical trial will evaluate the therapy in patients with active lupus nephritis or active SLE without renal involvement, with initial clinical data expected in mid-2024. This approach aims to leverage prior successful data in autoimmune therapies, potentially offering significant treatment advancements for patients with SLE.
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing
Cabaletta Bio reported its financial results for the fourth quarter and full year of 2022, highlighting expectations for Investigational New Drug (IND) clearance for CABA-201 in the first half of 2023. The company is focused on developing engineered T cell therapies targeting autoimmune diseases and anticipates generating initial clinical data for CABA-201 by mid-2024. Cabaletta has financial resources to support operations through the first quarter of 2025 and is actively progressing its pipeline with ongoing trials for other product candidates. However, risks associated with regulatory approvals and clinical trial outcomes persist.
Read more →CABACabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
Cabaletta Bio, Inc. (Nasdaq: CABA) will be represented by CEO Steven Nichtberger at the Cowen 43rd Annual Health Care Conference on March 7, 2023, in Boston, MA. The company focuses on developing curative targeted cell therapies for autoimmune diseases and will provide a live webcast of the event on its website. The CABA platform includes innovative strategies aimed at creating effective treatments for various autoimmune conditions.
Read more →CABACabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA) will be presenting at the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 12th in San Francisco. The company is recognized for its efforts in developing targeted cell therapies aimed at treating autoimmune diseases. CEO Steven Nichtberger will deliver the presentation, which will also be available via webcast on the company's website. This presentation is an opportunity for Cabaletta Bio to showcase its innovative CABA™ platform and its potential curative treatment strategies.
Read more →CABACabaletta Bio Announces $35 Million Offering PHILADELPHIA
Cabaletta Bio Announces $35 Million Offering PHILADELPHIA, Dec. 8, 2022 Cabaletta Bio, Inc. ( Cabaletta or the Company ) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoi
Read more →CABACabaletta Bio Announces $35 Million Offering
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today an
Read more →CABA▲ +7.2%on this news
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger
Read more →CABACabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update PHILADELPHIA
Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business PHILADELPHIA, Nov. 10, 2022 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients wi
Read more →CABACabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
– Company has obtained exclusive worldwide license for a fully human CD19 binder with clinical tolerability data that support potential clinical development in autoimmune diseases – – CABA-201 Investigational New Drug (IND) application planned for the first half of 2023 with ini
Read more →CABACabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and
Read more →CABACabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Pr
Read more →CABA▼ -7.5%on this newsshared move
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translationa
Read more →CABA▼ -33.9%on this news· ran to -48% by day 1
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes Trial PHILADELPHIA
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on PHILADELPHIA, Aug. 29, 2022 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune
Read more →CABA▲ +13.3%on this news
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update PHILADELPHIA
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update PHILADELPHIA, Aug. 11, 2022 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with
Read more →CABA▼ -13.3%on this news· ran to -29% by day 3
Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting
PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational
Read more →CABACabaletta Bio to Present at the H.C. Wainwright Global Investment Conference
PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Pres
Read more →CABA▲ +7.3%on this news· ran to +53% by day 3shared move
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update DesCAARTes trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be present
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update DesCAARTes trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 Multiple a
Read more →CABACabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May PHILADELPHIA
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific May 2, 2022 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with
Read more →CABACabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., Pre
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update DesCAARTes trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohort
Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update DesCAARTes trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected
Read more →CABACABALETTA BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Cabaletta Bio, Inc.
LEAD PLAINTIFF DEADLINE IS APRIL 29, 2022 NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) in t
Read more →CABACabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference
PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Pre
Read more →CABACabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the promotions
Read more →CABACabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABACabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABA▼ -73.1%on this news
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data o
Read more →CABACabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointmen
Read more →CABACabaletta Bio to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Compa
Read more →CABA▲ +5.1%on this news
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort relative to the first two low dose cohorts throughout the 28 days following infusion – – No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of October 31, 2021
Read more →CABA▲ +5.1%on this newsshared move
Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort with 500 million DSG3-CAART cells relative to th
Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort with 500 million DSG3-CAART cells relative to the first two low dose cohorts in DesCAARTes Phase 1 clinica
Read more →CABACabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021
– Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro – – Membrane proteome arrays screened with PLA2R CAAR candidates did not identify off-target interactions – – Pre-IND interaction with the Food
Read more →CABACabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven N
Read more →CABACabaletta Bio Announces Appointment of Michael Gerard as General Counsel
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael
Read more →CABA▲ +10%on this news
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort – – DSG3-CAART persistence observed in all three patients in the second dose cohort during the 28 days following infusion – – Do
Read more →CABACabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update Company continues to make progress on the DesCAARTes trial for DSG3-CAART; expects to report second and third cohort safety data in
Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update Company continues to make progress on the DesCAARTes trial for DSG3-CAART; expects to report second and third cohort safety data in 3Q21 and 4Q21, respectively, and data on target engagemen
Read more →CABACabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors Dr. Brun s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Ca
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors Dr. Brun s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta s rapidly emerging pipeline PHILADELPHIA, June 28
Read more →CABACabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – Second dose cohort to be initiated after the third patient completes 28 day follow up, absent any DLT – – Acute safety data from the second and
Read more →CABACabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – PLA2R-CAART announced as a new development program for patients
Read more →CABACabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates Acute safety data from the first cohort in the DesCAARTes trial announced today; no dose limiting toxicities (DLTs) or clinical
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates Acute safety data from the first cohort in the DesCAARTes trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose coho
Read more →CABACabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven N
Read more →CABACabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update PHILADELPHIA
Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update PHILADELPHIA, March 16, 2021 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therap
Read more →CABACabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABACabaletta Bio to Participate in Upcoming January Investor Conferences
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABACabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune diseases PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nas
Read more →CABACabaletta Bio to Participate in Upcoming December Investor Conferences
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABACabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update PHILADELPHIA, PA
Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update PHILADELPHIA, PA November 10, 2020 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pati
Read more →CABACabaletta Bio to Present at Upcoming Investor Conferences in October
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven N
Read more →CABACabaletta Bio to Present at Multiple Upcoming September Investor Conferences
PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participa
Read more →CABACabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy and did not demonstrate off-target toxicity DesCAARTes™ Phase 1 clinical trial
Read more →CABACabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update PHILADELPHIA
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapi
Read more →CABACabaletta Bio to Present at Multiple August Investor Conferences
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participat
Read more →CABACabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies
PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, In
Read more →CABACabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune
Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases PHILADELPHIA, May 28, 2020 Cabaletta Bio, Inc. (
Read more →CABACabaletta Bio to Present at Jefferies Virtual Healthcare Conference
PHILADELPHIA, May 27, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nic
Read more →CABACabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform
In vivo preclinical data show that Chimeric AutoAntibody Receptor (CAAR) T cells were able to specifically recognize and eliminate anti-MuSK antibody-expressing B cells while sparing control B cells PHILADELPHIA, May 18, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA
Read more →CABACabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update PHILADELPHIA, PA
Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update PHILADELPHIA, PA -- May 12, 2020 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patien
Read more →CABACabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of
Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update PHILADELPHIA, March 30, 2020 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies
Read more →CABAThe following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer se
Selective B cell ablation for autoimmune disease February 2020 Exhibit 99.1 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any que
Read more →CABACabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
PHILADELPHIA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABAFDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris PHILADELPHIA
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris PHILADELPHIA, Jan. 29, 2020 (GLOBE NEWSWIRE) Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies
Read more →CABACabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference
PHILADELPHIA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Ni
Read more →CABACabaletta Bio Announces Pricing of Initial Public Offering
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the pricing of
Read more →CABACabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
Study to be presented by the laboratory of University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta co-founder and Scientific Advisory Board co-chair, as a highlighted abstract at the American Neurological Association (ANA) 2019 Annual Meeting in St. Louis PHILAD
Read more →CABACabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris
First IND clearance of a product candidate derived from the CABA™ platform PHILADELPHIA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Company), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for the treatm
Read more →CABACabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel
PHILADELPHIA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, today announced the appointment of Brian Stalter as General Counsel. “Wi
Read more →CABACabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to its Board of Directors
RADNOR, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, announced today the appointment of Dr. Catherine Bollard, M.B.Ch.B., M.D., FRACP, F
Read more →CABACabaletta Bio to Present at the Cowen and Company 39th Annual Healthcare Conference
RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., Co-founder, Chief Executive Officer
Read more →CABACabaletta Bio Appoints Experienced Financial Executive, Richard Henriques, to its Board of Directors
RADNOR, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, announced today the appointment of Mr. Richard C. Henriques, Jr., MBA, to its Board
Read more →CABACabaletta Bio Appoints Anup Marda as Chief Financial Officer
Mr. Marda joins Cabaletta with 17 years of financial leadership experience RADNOR, Pa., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, has appo
Read more →CABACabaletta Bio to Present at the 37th Annual J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., co-founder, Chief Executive Officer an
Read more →CABACabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cell-Mediated Autoimmune Diseases
RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases, today announced that it has closed a $50 million Series B financing. The new investors
Read more →CABACabaletta Bio Expands Scientific Regulatory, and Cell Therapy Manufacturing Expertise with Scientific Advisory Board Additions
-- Carl June, M.D., who led discovery and development of the breakthrough CAR T platform at the University of Pennsylvania -- Jay Siegel, M.D., former head of Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research at FDA & retired Chief Biotechn
Read more →CABACabaletta Bio Emerges Out of University of Pennsylvania to Develop CAAR T Cell Technology to Treat B Cell-mediated Autoimmune Diseases
-- Signs exclusive license agreement and multi-year sponsored research agreements with University of Pennsylvania -- Completes $38 million Series A financing to advance lead asset, DSG3-CAART for mucosal pemphigus vulgaris, into clinical development RADNOR, Pa., Nov. 08, 2018 (
Read more →Competitive Position
How CABA ranks across every disease it competes inCompetitive Position is a premium feature
See how CABA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial